Echo IQ presents groundbreaking results from clinical studies

Echo IQ Limited (ASX:EIQ) has announced the groundbreaking results from two clinical studies evaluating the performance of its Heart Failure AI system. The studies demonstrated that the AI technology accurately detected heart failure in 86% of patients and 97% of high-risk individuals. These results were presented at the European Society of Cardiology (ESC) Congress 2024, showcasing the potential of Echo IQ's AI solution as a diagnostic aid for the detection of heart failure.

Executive commentary on groundbreaking results

Prof. David Playford, Echo IQ's Chief Medical Advisor, expressed, 'The results of these two clinical studies back up the groundbreaking initial results from application of the AI to the National Echo Database of Australia (NEDA). The findings illustrate the capacity of Echo IQ's AI-backed technology to enhance the diagnostic skills of doctors. Heart failure is a major global health priority, and widespread application of Echo IQ's heart failure AI has the potential to improve countless lives by enhancing the detection rates of heart failure.' Echo IQ Executive Chair, Mr Andrew Grover, added, 'To have been invited to present these results at the world's leading international cardiology conference has provided Echo IQ with an exceptional springboard to broaden its footprint in a major global market. The results and the feedback received from the event have highlighted that our innovation is a medical necessity for improving patient outcomes.'

Summary of groundbreaking results and outlook

The clinical studies demonstrated that Echo IQ's AI technology significantly improves the detection of heart failure, with an accuracy of 97% when used in collaboration with human review. This positions Echo IQ to positively impact heart failure health economics, with potential significant commercial interest and a clear pathway for FDA application. The company's AI-backed solution may enhance a doctor's potential to identify people with, or at risk of, heart failure, potentially optimizing treatment choices for these individuals. Echo IQ is focused on advancing its regulatory strategy with an application for US FDA clearance and engaging with leading global pharmaceutical companies and device manufacturers to capitalize on the commercial opportunities presented by these groundbreaking results.